These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17694358)

  • 1. Tandem mass spectrometric determination of succinylacetone in dried blood spots enables presymptomatic detection in a case of hepatorenal tyrosinaemia.
    Weigel JF; Janzen N; Pfäffle RW; Thiery J; Kiess W; Ceglarek U
    J Inherit Metab Dis; 2007 Aug; 30(4):610. PubMed ID: 17694358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
    Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
    Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
    la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
    Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
    Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
    Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening.
    Das AM; Mayorandan S; Janzen N
    Adv Exp Med Biol; 2017; 959():125-132. PubMed ID: 28755190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
    De Jesús VR; Adam BW; Mandel D; Cuthbert CD; Matern D
    Mol Genet Metab; 2014; 113(1-2):67-75. PubMed ID: 25066104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
    Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
    Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry.
    Al-Dirbashi OY; Rashed MS; Brink HJ; Jakobs C; Filimban N; Al-Ahaidib LY; Jacob M; Al-Sayed MM; Al-Hassnan Z; Faqeih E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):274-80. PubMed ID: 16384749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
    Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
    Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.
    Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC
    Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
    Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots.
    Allard P; Grenier A; Korson MS; Zytkovicz TH
    Clin Biochem; 2004 Nov; 37(11):1010-5. PubMed ID: 15498530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program.
    Zytkovicz TH; Sahai I; Rush A; Odewale A; Johnson D; Fitzgerald E; Britton D; Eaton RB
    Clin Biochem; 2013 May; 46(7-8):681-4. PubMed ID: 23462696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.
    Turgeon C; Magera MJ; Allard P; Tortorelli S; Gavrilov D; Oglesbee D; Raymond K; Rinaldo P; Matern D
    Clin Chem; 2008 Apr; 54(4):657-64. PubMed ID: 18281422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
    Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
    Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a neonate with hepatorenal tyrosinemia by combined routine newborn screening for succinylacetone, acylcarnitines and amino acids.
    Al-Dirbashi OY; Fisher L; McRoberts C; Siriwardena K; Geraghty M; Chakraborty P
    Clin Biochem; 2010 May; 43(7-8):691-3. PubMed ID: 19836366
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.
    Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H
    Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory monitoring of patients with hereditary tyrosinemia type I.
    Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
    Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
    la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
    Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
    [No Abstract]   [Full Text] [Related]  

  • 20. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
    Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
    Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.